Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Absci鈥檚 dense biotech disclosures can feel like parsing a lab notebook written in code. R&D capitalization rules, milestone accounting, and rapidly evolving regulatory language turn every 10-K into a puzzle. That鈥檚 why our SEC filings hub tackles the complexity head-on, turning 鈥淎bsci insider trading Form 4 transactions鈥� and clinical-stage risk factors into clear, decision-ready insights.
Need the latest numbers? Each Absci quarterly earnings report 10-Q filing is indexed the moment it posts to EDGAR, with AI-powered summaries highlighting cash runway, collaboration revenue swings, and pipeline spend. Material news breaks fast too鈥攐ur platform pushes alerts and plain-English takeaways for every Absci 8-K material events explained entry, so you know exactly what changed and why.
Curious whether executives are buying ahead of data readouts? Track Absci Form 4 insider transactions real-time and dive deeper with Absci executive stock transactions Form 4 tables already totaled for you. Preparing a valuation model? The Absci annual report 10-K simplified section distills 200-plus pages into key financials, IP assets, and regulatory risks. Governance analysts can compare board pay with the Absci proxy statement executive compensation snapshot, while newcomers benefit from understanding Absci SEC documents with AI through concise, jargon-free briefs.
- AI summaries translate complex biotech language into investor-ready points.
- AG真人官方-time feeds cover every form鈥攆rom 10-K to 8-K鈥攆or complete Absci earnings report filing analysis.
- Searchable database links each disclosure to the questions professionals actually ask.
Spend less time decoding filings and more time acting on insights鈥攐ur platform turns Absci鈥檚 regulatory maze into a straight path.
Absci Corporation filed Amendment No. 1 to its Current Report to correct a clerical error in the Original Form 8-K. The amendment fixes an incorrect reference to the press release date, changing it from June 12, 2025 to August 12, 2025, and corrects coding for Item 9.01. On August 12, 2025 the company furnished a press release announcing results for the quarter ended June 30, 2025 (Exhibit 99.1) and a corporate presentation with internal pipeline updates (Exhibit 99.2). The furnished materials are stated as "furnished" and not "filed."
Absci Corporation filed a preliminary Form S-3 shelf registration to offer up to $400,000,000 of securities, including common stock, preferred stock, debt securities, warrants and units. The filing carries forward $75,175,613 of unsold securities from a prior registration and includes a sales agreement prospectus for up to $100,000,000 of common stock to be sold under a sales agreement with TD Securities (USA) LLC dated August 12, 2025. The company鈥檚 common stock trades on Nasdaq under ABSI and closed at $2.92 on August 7, 2025.
Absci describes its Integrated Drug Creation platform using generative AI for antibody design, reports over 25 partnered programs, and highlights internal programs ABS-101 (Phase 1 initiated May 2025; Phase 1b/2a anticipated H1 2026) and ABS-201 (IND filing targeted H1 2026; interim Phase 1 read-out targeted H2 2026). The prospectus is preliminary, references risk factors on page 10, notes the company is an emerging growth company and a smaller reporting company, and states proceeds will be used for general corporate purposes with management retaining broad discretion.
Absci Corporation reported reduced partner program revenue and higher research spending while advancing its AI-driven antibody pipeline. Revenue was $0.6 million for Q2 and $1.8 million for the six months ended June 30, 2025, down from $1.3 million and $2.2 million in the prior-year periods, respectively. Research and development expense rose 34% year-over-year to $36.8 million for the six months ended June 30, 2025, driven primarily by advancement of drug creation and external preclinical and clinical costs.
The company recorded a net loss of $30.6 million for the quarter and $56.9 million for the six months, with basic and diluted net loss per share of $0.45 for the six months. Cash, cash equivalents and short-term investments totaled $117.5 million at June 30, 2025. Subsequent equity raises after quarter-end generated net proceeds of approximately $60.6 million including an ATM sale and a public offering; Absci also completed a $20.0 million PIPE strategic collaboration with AMD in January 2025. The company initiated dosing in a Phase 1 study of ABS-101 in May 2025 and expects interim and IND-related milestones for ABS-101 and ABS-201 in 2025-2026. Partner revenue remained concentrated, with two partners contributing ~99% of Q2 partner revenue.
On August 12, 2025, Absci Corporation announced that it is reporting its financial results for the second quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1. The filing states the press release and related information are being furnished rather than filed for purposes of Section 18 of the Exchange Act. On the same date the company released and made available a corporate presentation containing certain internal pipeline program updates, which is filed as Exhibit 99.2 and posted in the "News & Events" section of the company website. This Form 8-K notifies investors of the availability of the press release and presentation, but it does not include the underlying financial figures or detailed results within the body of the filing.
FAQ
What is the current stock price of Absci (ABSI)?
What is the market cap of Absci (ABSI)?
